Ibrutinib Dosage Guide: Standard Doses for CLL, MCL, and WM

Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor that was first approved by the U.S. FDA in November 2013 for the treatment of mantle cell lymphoma (MCL). It has been included in China's National Reimbursement Drug List (Category B).

Indications for Ibrutinib

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

For the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, including CLL/SLL with a chromosomal abnormality (deletion 17p13.1). The U.S. Food and Drug Administration (FDA) granted orphan drug designation for this use.

Waldenström's Macroglobulinemia (WM)

For the treatment of Waldenström's macroglobulinemia (WM). The FDA granted orphan drug designation for this use.

Chronic Graft-Versus-Host Disease (cGVHD)

For the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 1 year and older who have failed one or more prior lines of systemic therapy. The FDA granted orphan drug designation for this use.

Screening and Monitoring for Ibrutinib

Pre-treatment Screening

(1) Assess cardiac history and cardiac function at baseline.

(2) Assess baseline risk for tumor lysis syndrome.

(3) Verify pregnancy status in females of reproductive potential.

(4) Assess bilirubin and transaminase levels at baseline.

Patient Monitoring

(1) Monitor complete blood counts (CBC) monthly.

(2) Monitor for signs and symptoms of bleeding. Concurrent use of antiplatelet or anticoagulant therapy increases the risk of major bleeding.

(3) Monitor for signs and symptoms of infection, including fever.

(4) Monitor patients for symptoms of arrhythmias and heart failure.

(5) Monitor blood pressure.

(6) Monitor for tumor lysis syndrome.

(7) Monitor bilirubin and transaminases. Monitor more frequently in patients who develop liver function test abnormalities or clinical signs/symptoms of hepatotoxicity during treatment.

Dosing and Administration Considerations for Ibrutinib

Administration Method

(1) For oral administration.

(2) Administer orally once daily at approximately the same time each day.

(3) Swallow capsules whole with a glass of water. Do not open, break, or chew.

(4) Swallow tablets whole with a glass of water. Do not cut, crush, or chew.

(5) Refer to the full instructions for use in the prescribing information for detailed administration instructions for the oral suspension.

Missed Dose

If a dose is missed, take the missed dose as soon as possible on the same day and return to the normal schedule the following day. Do not take an extra dose on the same day to make up for a missed dose.

Recommended Dosage for Ibrutinib

Pediatric Recommended Dosage

(1) Chronic Graft-Versus-Host Disease (cGVHD)

Pediatric patients 12 years and older: 420 mg orally once daily.

Pediatric patients 1 year to less than 12 years: 240 mg/m² orally once daily (maximum dose 420 mg). Continue treatment until cGVHD progression, recurrence of underlying malignancy, or unacceptable toxicity. Discontinue treatment when cGVHD therapy is no longer required.

Adult Recommended Dosage

(1) Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

420 mg orally once daily (as monotherapy, in combination with bendamustine and rituximab, or in combination with rituximab or obinutuzumab). Continue treatment until disease progression or unacceptable toxicity.

If administering on the same day, consider giving ibrutinib prior to rituximab or obinutuzumab.

(2) Waldenström's Macroglobulinemia (WM)

420 mg orally once daily (as monotherapy or in combination with rituximab). Continue treatment until disease progression or unacceptable toxicity.

If administering on the same day, consider giving ibrutinib prior to rituximab.

(3) Chronic Graft-Versus-Host Disease (cGVHD)

420 mg orally once daily. Continue treatment until cGVHD progression, recurrence of underlying malignancy, or unacceptable toxicity. Discontinue treatment when cGVHD therapy is no longer required.

Dosage Adjustments in Special Populations for Ibrutinib

Hepatic Impairment

(1) Adult B-cell Malignancies (including CLL/SLL or WM):

Mild (Child-Pugh Class A): Reduce dose to 140 mg once daily.

Moderate (Child-Pugh Class B): Reduce dose to 70 mg once daily.

Severe (Child-Pugh Class C): Avoid use.

(2) Patients with Chronic Graft-Versus-Host Disease:

Patients 12 years and older with total bilirubin >1.5-3x ULN (unless non-hepatic or due to Gilbert's syndrome): Recommended dose is 140 mg once daily.

Patients 1 to <12 years with total bilirubin >1.5-3x ULN (unless non-hepatic or due to Gilbert's syndrome): Recommended ibrutinib dose is 80 mg/m²/day.

Total bilirubin >3x ULN (unless non-hepatic or due to Gilbert's syndrome): Avoid use.

Renal Impairment

No specific dose recommendations are currently available.

Geriatric Use

No specific dose recommendations are currently available.

Common Adverse Reactions to Ibrutinib

B-cell Malignancies (≥30%)

Thrombocytopenia, diarrhea, anemia, neutropenia, musculoskeletal pain, rash, bruising, nausea, fatigue.

Chronic Graft-Versus-Host Disease (≥20%; Adult and Pediatric Patients)

Fatigue, anemia, bruising, diarrhea, thrombocytopenia, musculoskeletal pain, pyrexia, muscle spasms, stomatitis, nausea, hemorrhage, abdominal pain, headache, pneumonia.

Warnings and Precautions for Ibrutinib

Hemorrhage

Serious (Grade 3 or higher) bleeding events have occurred, including intracranial hemorrhage, subdural hematoma, gastrointestinal bleeding, hematuria, and post-procedural bleeding.

The risk of bleeding events is increased when ibrutinib is used concomitantly with antiplatelet or anticoagulant therapy. Weigh the potential benefits and risks of concomitant anticoagulant or antiplatelet therapy. Monitor for signs of bleeding.

Infections

Serious infections (bacterial, viral, or fungal), progressive multifocal leukoencephalopathy, and Pneumocystis jirovecii (formerly P. carinii) pneumonia have occurred.

Monitor for signs and symptoms of infection and initiate appropriate anti-infective therapy as clinically indicated. Consider prophylaxis according to the current standard of care in patients at high risk for opportunistic infections.

Cytopenias

Cytopenias, including thrombocytopenia, anemia, and neutropenia, have occurred. Severe (Grade 3 or 4) cytopenias were observed in patients with B-cell malignancies treated with single-agent ibrutinib.

Monitor complete blood counts monthly. Reduce dose or interrupt treatment if myelosuppression occurs.

Cardiac Arrhythmias, Heart Failure, and Sudden Death

Serious cardiac arrhythmias and heart failure (sometimes fatal) have occurred, including (Grade 3 or higher) ventricular tachycardia, atrial fibrillation, and atrial flutter.

Risk is increased in patients with cardiac risk factors, hypertension, diabetes mellitus, acute infections, or a history of arrhythmias. Reports of sudden death or death from cardiac causes have occurred.

Hypertension

Hypertension (including Grade 3 or higher) has been reported. Monitor blood pressure. Initiate or adjust anti-hypertensive therapy as clinically indicated if hypertension occurs.

Second Primary Malignancies

Occurrences of other malignancies have been reported, including non-skin carcinomas. Non-melanoma skin cancer is the most common second primary malignancy.

Hepatotoxicity, Including Drug-Induced Liver Injury

Hepatotoxicity has been reported, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI).

Assess bilirubin and transaminases at baseline and throughout treatment. Monitor liver function tests and clinical signs/symptoms of hepatotoxicity more frequently in patients who develop liver function test abnormalities after starting ibrutinib.

Tumor Lysis Syndrome

Tumor lysis syndrome has been reported infrequently. Assess baseline risk for tumor lysis syndrome and take appropriate precautions. Monitor patients closely and treat as clinically indicated.

Fetal/Neonatal Morbidity and Mortality

Based on animal studies, may cause fetal harm. Verify pregnancy status in females of reproductive potential before initiating ibrutinib. Advise patients of the potential hazard to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment and for one month after the last dose.

Use in Specific Populations for Ibrutinib

Pregnancy

Based on animal studies, may cause fetal harm. Verify pregnancy status before treatment. If used during pregnancy, advise about the potential risk.

Lactation

It is unknown whether the drug is present in human milk or its effects on the breastfed infant. Avoid breastfeeding during treatment and for one week after the last dose.

Females and Males of Reproductive Potential

Verify pregnancy status before treatment. Both male and female patients should use effective contraception during treatment and for one month after the last dose.

Pediatric Use

Safety and effectiveness for the treatment of chronic graft-versus-host disease have been established in patients ≥1 year of age.

Safety in patients <1 year of age or for use in CLL/SLL or Waldenström's macroglobulinemia has not been established.

Geriatric Use

Efficacy was similar compared to younger adults, but adverse reactions like anemia and pneumonia were more frequent.

Hepatic Impairment

Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). Reduce dose and monitor closely in mild to moderate impairment.

Renal Impairment

No dose adjustment is needed for mild to moderate impairment (creatinine clearance >25 mL/min). No experience in severe impairment or dialysis patients.

Drug Interactions with Ibrutinib

Drugs and Foods Affecting Hepatic Microsomal Enzymes

CYP3A Inhibitors: Concomitant use with strong or moderate CYP3A inhibitors may increase ibrutinib plasma concentrations, increasing the risk of drug-related toxicity.

CYP3A Inducers: Concomitant use with strong or moderate CYP3A inducers may decrease ibrutinib plasma concentrations.

Avoid concomitant use with strong CYP3A inducers.

Substrates of Efflux Transport Systems

Concomitant use with orally administered P-gp or BCRP substrates (e.g., digoxin, methotrexate) may increase the concentration of the substrate drug.

Specific Drugs and Foods

Anticoagulants: May increase the risk of bleeding events.

Antiplatelet Agents: May increase the risk of bleeding events.

Grapefruit or Grapefruit Juice: Grapefruit products are moderate to strong CYP3A inhibitors; may increase ibrutinib concentration. Avoid concomitant use.

Seville Oranges or Orange Juice: Seville orange products are moderate to strong CYP3A inhibitors; may increase ibrutinib concentration. Avoid concomitant use.

Note: Please refer to the official product label for detailed information. Always follow the prescription and medical advice.

Storage for Ibrutinib

Capsules

Store at 20-25°C (excursions permitted between 15-30°C). Dispense in original package prior to dispensing.

Tablets

Store at 20-25°C (excursions permitted between 15-30°C). Store in the original package.

Oral Suspension

Store at 2-25°C; do not freeze. Dispense in original sealed container; do not use if seal is missing or broken. Discard any remaining unused oral suspension 60 days after first opening the bottle.